Abstrait
Poser la question sous cette forme paraît impliquer une réponse évidente. L’amélioration de la qualité de vie est un objectif premier de l’activité médicale, quelle qu’en soit sa situation: prévention, dépistage, thérapeutique adjuvante ou palliative; le patient doit pouvoir espérer, sinon tirer, un bénéfice du geste entrepris. L’évaluation des avantages, quels qu’ils soient, doit être contrebalancée par celle des inconvénients.
Preview
Unable to display preview. Download preview PDF.
Références
Wood WC, Muss HB, Solin LJ, Olopade OI (2005) Malignant tumors of the breast. In: De Vita VT, Hellman S, Rosenberg SA. Cancer. Principles and Practice of Oncology. Lippincot Williams and Wilkins: 169–231
Krakowski I, Boureau F, Bugat R et al. (2004) Pour une coordination des soins de support pour les personnes atteintes de maladies graves: proposition d’organisation dans les établissements de soins publics et privés. Oncologie 6: 7–15.
Von Minckwitz G, for The Breast Commission of the German Gynaecological Oncology Working Group (2006) Evidence-based treatment of metastatic breast cancer-2006 recommendations by the AGO Breast Commission. Eur J Cancer 2897–908
Beslija S, Bonneterre J, Burstein H et al. (2006) Second consensus on medical treatment of metastatic breast cancer. Ann. Oncol 18: 215–25
Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force (2007) Metastatic breast cancer. The Breast 16: 9–10
Smith I (2006) Goals of treatment for patients with metastatic breast cancer. Sem Oncol 33: S2–S5
Zittoun R. Dictionnaire de cancers de A à Z, FNCLCC. Qualité de vie. http://www.fnclcc.fr/fr/patients/dico/alpha.php
ASCO (1996) Outcomes of cancer treatment for technology assessment and cancer tratment guidelines. J Clin Oncol 14: 671–9
Conroy T (2006) La qualité de vie: un élément dans l’élaboration de la stratégie thérapeutique? Oncologie 8: 477–82
Marino P, Moatti JP (2006) Mesurer la qualité de vie: une nécessité en thérapeutique cancérologie. Oncologie 8: 454–9
Buron C, Livartowski A (2006) Prise en compte simultanée de la qualité de vie et de la quantité de vie: application à la cancérologie. Oncologie 8: 483–8
Mackey JR, Mastro L, Sormani MP et al. (2006) Trastuzumab prolongs progression — free survival in hormone — independent and HER2 — positive metastatic breast cancer. Breast Cancer Res Treat 100Suppl. 1: S5
Pierga JY, Robain M, Jouve M et al. (2001) Response to chemotherapy is a very major parameter — influencing long-term survival of metastatic breast cancer patients. Ann Oncol 12: 231–7
Bruzzi P, Del Mastro L, Sorani MP et al. (2005) Objective response to chemotherapy as a potential surrogate end point of survival metastatic breast cancer patients. J Clin. Oncol. 23: 5117–25
Geels P, Eisenhauer E, Bezjak A et al. (2000) Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18: 2395–405
Sledge GW, Neuberg D, Bernardo P et al. (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588–92
Seidman AD (2003) Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism? (Editorial) J Clin Oncol 21: 577–9
Overmeyer B (2003) Combination chemotherapy for metastatic breast cancer: reaching for the cure. (Editorial). J Clin Oncol 21: 580–2
Stadtmauer EA, O’Neil A, Goldstein LJ et al. (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoïetic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 342: 1069–76
McQuellon RP, Muss HB, Hoffman SL et al. (1995) Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 13: 858–68
Nooij MA, De Haes JC, Beex LV et al. (2003) Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists’ preferences. Eur J Cancer 39: 614–21
Brun B, Benchalal M, Lebas C et al. (1997) Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment. Cancer 79: 2137–46
Modi S, Seidman A (2005) Combination versus sequentiel single-agent therapy for the treatment of metastatic breast cancer. Eur J Cancer Suppl 3: 3–8
Porkka K, Blomquvist C, Rissanen P et al. (1994) Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol 12: 1639–47
Cardoso F, Di Leo A, Lohrisch C et al. (2002) Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 13: 197–207
Bouleuc C, Copel L (2007) Les aspects cliniques, éthiques et relationnels de l’arrêt de la chimiothérapie. Réflexions Med Oncol 17: 39–43
Aubry R, d’Herouville D et al. (2005) Soins palliatifs et soins de support. Oncologie 7: 203–8
Baines M (1994) Le concept de douleur globale. In: Saunders C, ed. Soins palliatifs, une approche pluridisciplinaire. Paris, Lamarre, coll Infirmière, société et avenir
Molassiotis A, Scott J et al. (2006) Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer 14: 260–7.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag France
About this chapter
Cite this chapter
Kerbrat, P., Botton, E. (2007). Soins palliatifs: peut-on parler de qualité de vie en phase métastatique?. In: Cancer du sein avancé. Springer, Paris. https://doi.org/10.1007/978-2-287-72615-6_18
Download citation
DOI: https://doi.org/10.1007/978-2-287-72615-6_18
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-72614-9
Online ISBN: 978-2-287-72615-6